Skip to main content
APRE
NASDAQ Life Sciences

Aprea Reports Interim Phase 1 APR-1051 Data: Two PRs, 84% Target Engagement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.53
Mkt Cap
$6.998M
52W Low
$0.39
52W High
$1.49
52W Position info
36% above low
Off High info
64% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

APRE sits 36% above its 52-week low of $0.39.

Summary

Aprea presented interim Phase 1 data for WEE1 inhibitor APR-1051 showing two partial responses in PPP2R1A-mutated uterine cancers, five durable stable-disease patients, and WEE1 target engagement in 84% of evaluable patients, with a manageable safety profile. Enrollment is being refocused on uterine serous carcinoma and cyclin E-overexpressing ovarian cancer.


Key Events · Product Development and Regulatory · APRE

  • Interim Phase 1 Data Show Two Partial Responses

    Of 56 patients treated in ACESOT-1051 as of the November 1, 2026 cutoff, 43 were evaluable: one confirmed and one unconfirmed RECIST 1.1 partial response in PPP2R1A-mutated uterine cancers, plus five stable-disease patients lasting more than four months.

  • WEE1 Target Engagement Confirmed in 84%

    Paired skin biopsies showed at least 50% reduction in pCDK1-Y15 in 21 of 25 evaluable patients (84%) across multiple dose levels, supporting once-daily dosing with an approximately 18-hour median half-life.

  • Manageable Safety With One Dose-Limiting Toxicity

    One DLT (AST/ALT elevation without bilirubin rise at 50 mg) among 56 patients; Grade 3/4 neutropenia in 4 patients (7%) with no febrile neutropenia, and two Grade 3 pneumonitis events (4%).

  • Enrollment Refocused on USC and Cyclin E PROC

    Aprea plans to enroll at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer, expanding to more than 10 sites, with dose escalation and backfill enrollment completion expected in Q2 2027.


Analysis · APRE · Life Sciences

Aprea's lead asset APR-1051 has delivered its first real clinical readout: two partial responses (one confirmed, on treatment beyond 10 months) in PPP2R1A-mutated uterine cancers, plus five stable-disease patients lasting over four months out of 56 treated. Equally important is the tolerability picture — a single dose-limiting toxicity and only 7% Grade 3/4 neutropenia with no febrile neutropenia — because prior WEE1 inhibitors were killed by narrow therapeutic windows. Enrollment is now being narrowed to uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, with dose escalation and backfill enrollment targeted for completion in Q2 2027. For a company with a market value under $10 million, this is the evidence that determines whether the program is partnerable or fundable; the $37.8M cash position reported in the November 4 10-Q runs into Q1 2028, so the next hard constraint is the January 19, 2027 Nasdaq bid-price deadline, not cash.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APRE was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.39 to $1.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APRE - Latest Insights

APRE
Aug 12, 2026, 8:39 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.6601
Real-time Price: $0.5304 info
Change: -$0.1297 (-20%) info
Market Cap: $6.998M info
APRE
Jul 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.6299
Real-time Price: $0.5304 info
Change: -$0.0995 (-16%) info
Market Cap: $6.998M info
APRE
Jul 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.631
Real-time Price: $0.5304 info
Change: -$0.1006 (-16%) info
Market Cap: $6.998M info
APRE
Jun 17, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7798
Real-time Price: $0.5304 info
Change: -$0.2494 (-32%) info
Market Cap: $6.998M info
APRE
Jun 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9076
Real-time Price: $0.5304 info
Change: -$0.3772 (-42%) info
Market Cap: $6.998M info